Nicholas Patrick McAndrew
University of California, Los Angeles · 80 works · 1,131 citations · h-index 14
Top works
- Ribociclib plus Endocrine Therapy in Early Breast Cancer
- Challenges in the clinical utility of the serum test for HER2 ECD
- Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
- A careful reassessment of anthracycline use in curable breast cancer
- Advances in Targeted Therapies for Triple-Negative Breast Cancer
- Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
- Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.
- Management of ER positive metastatic breast cancer
- Early treatment-related neutropenia predicts response to palbociclib
- Effects of systemic inflammation on relapse in early breast cancer
- TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
- Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
- Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.
- 218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results
- TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.
- Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
- Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
- Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis
- Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer.
- Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor